Skinvisible Unveils Promising Data on Transdermal Obesity Formulations
Skinvisible Pharmaceuticals announces breakthrough data on transdermal obesity drug delivery using Invisicare technology. Studies show up to 69% drug penetration, offering a non-invasive alternative to injections. Skinvisible seeks partners to bring transdermal obesity therapies to market.
